T Cell Leukemia-associated Human Notch/Translocation-associated Notch Homologue Has IκB-like Activity and Physically Interacts with Nuclear Factor-κB Proteins in T Cells

By Ennan Guan,* Jinhai Wang,* Jorge Laborda,* Michael Norcross,* Patrick A Baeuerle,† and Thomas Hoffmann*

From *Laboratory of Cell Biology, Divisions of Monoclonal Antibodies and Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892; and †Department of Drug Discovery, Tularik Inc., San Francisco, CA 94080

Summary

Translocation-associated Notch homologue (TAN-1), a gene originally cloned from the translocation breakpoint of a human T cell leukemia carrying a 9;7(q34.3) translocation, encodes a protein belonging to the Notch/Lin-12/Glp-1 receptor family. These receptors mediate the specification of numerous cell fates during development in invertebrates and vertebrates. The intracellular portion of Notch/TAN-1 contains six ankyrin repeats that are similar to those found in cytoplasmic IκB proteins. IκB proteins are specific inhibitors of nuclear factor (NF)-κB transcription factors. Here we show that TAN-1 has functional properties of an IκB-like regulator with specificity for the NF-κB p50 subunit. A recombinant polypeptide corresponding to the cytoplasmic portion of TAN-1 (TAN-1c) specifically inhibited the DNA binding of p50-containing NF-κB complexes. When overexpressed in an appropriate cell line, TAN-1c prevented κB-dependent transactivation in transient reporter gene assays in a fashion similar to the structurally related protein, Bcl-3. TAN-1c could activate κB-dependent gene expression by attenuating the inhibitory effect of an excess of p50 homodimers. Immunoprecipitation experiments showed that the TAN-1 from a T cell line is associated with NF-κB containing p50 and p65 subunits. These observations indicate that TAN-1c may directly engage NF-κB transcription factors and modulate nuclear gene expression.

The Notch/Lin-12 family of transmembrane receptors is believed to play a pivotal role in development by regulating cell-fate decisions (1–5). Extensive genetic studies of the Notch locus in invertebrates have revealed its roles during embryonic development of eyes, bristles, central and peripheral nervous system, muscles, and wings (6, 7). These observations have led to the hypothesis that Notch may not directly specify cell fate but rather inhibits specific signals required for cell-type specification. Translocation-associated Notch homologue (TAN-1), the human counterpart of the Drosophila Notch, was discovered as a t(7;9) (q34.3) reciprocal translocation in the TCR-β locus in certain T lymphocytic leukemias (8). Altered expression of Notch proteins is also associated with cell fate abnormalities such as cervical and other epithelial neoplasias (9).

TAN-1 is expressed in a broad range of human tissues and is relatively highly expressed in lymphoid organs and the central nervous system. TAN-1 consists of an extracellular region containing 36 epidermal growth factor (EGF)-like segments, 3 Notch/Lin-12 repeats, and an intracellular portion containing 6 tandemly arranged ankyrin repeats, in addition to other functional domains (8). The extracellular portion of Notch proteins is thought to mediate receptor-ligand interactions (10, 11). The intracellular ankyrin repeats of Notch may be involved in protein–protein interactions that mediate transmission of the Notch signal to the nucleus (12–14).

Nuclear Factor (NF)-κB/Rel transcription factors are involved in the inducible expression of many genes containing κB-binding motifs, including certain genes with important functions in immune, inflammatory, and acute phase responses (15, 16). In higher vertebrates, the DNA-binding subunits of NF-κB/Rel proteins encompass p50, p65 (RelA), c-Rel, p52, and RelB (17–22). These can to a limited extent homo- and heterodimerize, resulting in complexes with distinct DNA-binding specificity (23–26). Multiple stimuli cause a translocation of cytosolic NF-κB/Rel factors to the nucleus where they transactivate κB-dependent genes. This process is controlled by a class of inhibi-
tory molecules, termed IκB proteins, that retain NF-κB/Rel factors in the cytoplasm and suppress their DNA-binding activity (26–28). These include IκB-α, IκB-β, Bcl-3, and the NF-κB precursor proteins p100 and p105 (29–35). Upon activation, IκB proteins undergo a phosphorylation-controlled proteolysis that allows the released NF-κB/Rel factor to enter the nucleus and transactivate genes (24, 36–38). A common structural feature of IκB proteins is the presence of five to seven closely adjacent ankyrin repeats. Mutational analysis has shown that each of these repeats is required for the functional integrity of the proteins (32, 39).

Bcl-3 is an exceptional IκB protein. While it inhibits the DNA binding of transcriptionally inactive p50 dimers, it can also associate with p52 dimers on DNA and provide the NF-κB/Rel protein with transactivating potential (30, 31, 33, 34, 40). Like TAN-1, Bcl-3 was identified as a gene aberrantly expressed as a consequence of a translocation in leukemic cells (41). The structural similarity between the cytoplasmic portion of TAN-1 and various IκB proteins prompted us to investigate the potential of TAN-1 to function as a membrane-bound and, eventually, cytoplasmically released form of IκB. Here we report that the cytoplasmic portion of TAN-1 (TAN-1), is a specific inhibitor of NF-κB complexes containing the p50 subunit. In cells overexpressing TAN-1, endogenous NF-κB is found associated with the receptor. We infer that the TAN-1 receptor can regulate nuclear gene expression by directly interacting with members of the NF-κB transcription factor family.

Materials and Methods

Purification of Glutathione-S-transferase–TAN-1 Fusion Protein and Antibody Production. The expression construct for glutathione-S-transferase (GST)–TAN-1 contained a coding sequence from amino acids 1774 to 2230 cloned into the pGEXKAT vector (Pharmacia, Uppsala, Sweden). Control protein, GST, was prepared from cells containing unmodified pGEXKAT vector. GST–TAN-1 fusion protein and GST were expressed in BL21(DE3) (Novagen, Inc., Madison, WI). Soluble protein extracts were prepared by mild sonication. Cell debris were removed by centrifugation. The supernatant was loaded onto a Sepharose-glutathione affinity column, washed with solution A, 0.5% Triton X-100 in 0.5 M NaCl, and the NF-κB precursor proteins p100 and p105 were expressed in BL21(DE3) (Novagen, Inc., Madison, WI). Control protein, GST, was prepared from cells according to the manufacturer’s instructions. This purified GST–TAN-1 fusion protein was used to immunize rabbits for antibody production.

Ectodomainic Mobility Shift Assay. Jurkat T cells were cultured in RPMI-1640 supplemented with 10% FCS and treated with 50 ng/ml PMA (Sigma, Chemical Co., St. Louis, MO) for 3 h. Nuclear extracts were prepared as described elsewhere (42). Briefly, pelleted cells were suspended in 5 vol of cold PBS and collected by centrifugation at 4°C. The cells were suspended in 5 vol packed cell pellet of buffer A containing 10 mM Hepes (pH 7.9), 1.5 mM MgCl₂, 10 mM KCl, and 0.5 mM dithiothreitol (DTT). The cells were allowed to stand for 10 min and were then centrifuged for 10 min at 2,000 rpm in a rotor (model HG4L, Sorval, Newtown, CT). 2 vol of buffer A was added to the pellet. The cells were lysed by a glass homogenizer (Kontes Co., Vineland, NJ). The homogenate was centrifuged at 2,000 rpm to pellet nuclei. The nuclear pellet was subjected to a second centrifugation at 25,000 g for 20 min. The pellet was resuspended in 3 ml of buffer C (20 mM Hepes, pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT) per 10⁶ cells and lysed with a Kontes glass homogenizer. The resulting suspension was centrifuged at 25,000 g for 20 min. The supernatant was frozen at −80°C. DNA-protein–binding reactions were carried out in 10 mM Tris, pH 7.5, 10 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 2 μg poly(dI-dC) (Pharmacia), and 5% glycerol in a final vol of 20 μl. The reaction contained 6 μg of nuclear extract and five-end-labeled Ig enhancer binding probes. GST-TAN-1 or GST was added directly to the binding reaction. The reaction was kept at room temperature for 30 min and loaded on a nondenaturing 6% polyacrylamide gel using 0.5 × Tris/Borate/EDTA buffer for 3 h at 150 V. P50 and p65 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Expression Constructs and In Vitro Translation. The TAN-1 construct contains the sequence of the TAN-1 intracellular portion including amino acids 1774 to 2230, which is identical to the sequence of GST–TAN-1 fusion protein. P50 and p65 constructs have been described elsewhere (22). The expression of p50, p65, TAN-1, and Bcl-3 was directed by the expression vector RC CMV (Invitrogen, San Diego, CA). The Bcl-3 construct was a kind gift of Dr. I.M. Verma (Salk Institute, San Diego, CA). The reporter plasmids contain a luciferase gene driven by the six reiterated kB sites. Translation of full-length p50 and p65 was performed in the presence or absence of L-[35S]methionine using wheat germ extracts according to manufacturer’s protocols (Promega, Corp., Madison, WI). Translated products were analyzed by SDS-PAGE (10%) followed by autoradiography.

Cell Culture and Transient Transfection Experiments. NTera-2 cells (American Type Culture Collection [ATCC], Rockville, MD) were grown in DMEM containing 10% FCS. NTera-2 cells were transfected with expression vectors in a 6-well plate in the presence of lipofectamine (GIBCO BRL, Gaithersburg, MD). The transfection was performed according to the manufacturer’s standard protocols. After 48 h, the cells were harvested and extracts assayed for luciferase activity using a kit (Promega Corp.) according to the manufacturer’s instructions.

Immunoprecipitation and Western Blot Analysis. Sup-T1 cells (from Dr. J. Hoxie) and U266 cells (ATCC) were extracted in 1% Triton X-100 (Sigma Chemical Co.), 50 mM Tris, pH 7.5, 1 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 1 μg/ml E64, and 40 μg/ml bestatin (Boehringer Mannheim, Mannheim, Germany) at 10⁶ cells/ml for 1 h on ice. Soluble detergent extracts were incubated with p50 or p65 antibodies (Santa Cruz Biotechnology) for 2 h at room temperature and then at 4°C overnight after the addition of protein G–Sepharose beads. The beads were washed five times with 140 mM NaCl, 10 mM Tris, pH 7.5, and 0.5% Triton X-100, and then boiled in SDS sample loading buffer under reducing conditions for 10 min, and run on a 4–20% SDS-PAGE, followed by electrotransferring to polyvinylidene difluoride membranes. Membranes were blocked with 5% BSA in TBS for 2 h, and then sequentially incubated with rabbit anti-TAN-1 antibody or preimmune IgG, followed by alkaline phosphatase–conjugated anti–rabbit IgG heavy and light chains (Bio-Rad Laboratories). Alkaline phosphatase substrate was detected by Lumi-Phos™ 530 (Boehringer Mannheim).
Results

**TAN-1C Is a Specific Inhibitor of NF-κB.** The mechanism by which proteins in the Notch family function is incompletely understood. A recent study showed that a construct consisting primarily of six ankyrin repeats of germline proliferation-1, a member of the Notch family, is sufficient to control downstream regulators of cell fate in *Caenorhabditis elegans* (12). Another report (14) showed that a cytoplasmic protein, Deltex, positively regulates the Notch pathway through interactions with the Notch ankyrin repeats. A GST fusion protein, corresponding to the Notch/TAN-1 intracellular domain containing six ankyrin repeats and NH2- and COOH-terminal flanking sequences of TAN-1 (amino acids 1774-2230), was produced in *Escherichia coli* and purified by affinity chromatography. GST was also expressed for use as a control and purified in the same way. Both proteins were examined for inhibition of NF-κB DNA binding to a consensus κB site. In an electrophoretic mobility shift assay (EMSA) with nuclear extracts from Jurkat T cells, TAN-1C inhibited DNA binding of NF-κB that had been activated by treatment of cells with PMA (Fig. 1A, lane 5; Fig. 1B, lanes 2-4). Treatment of DNA-binding reactions with specific antibodies showed that the NF-κB complex contained both p50 and p65 subunits (Fig. 1B, lanes 6 and 7). The activity of GST-TAN-1C was specific since it did not affect the activity of endogenous octamer-binding transcription factor 1 (OTF1) (Fig. 1C) and the GST portion alone showed no inhibitory effect in EMSA (Fig. 1A, lane 6; Fig. 1B, lane 5). For complete inhibition of the NF-κB complex, 4 pmol of GST-TAN-1 was required, which is comparable to the amount of IκB-α or Bcl-3 necessary for inhibition of NF-κB (29, 30).

**NF-κB Subunit Specificity of TAN-1C.** Using in vitro-translated p50 or p65, we tested whether the IκB-like activity of GST-TAN-1C was specific for NF-κB subunits. GST-TAN-1C effectively inhibited DNA binding of p50 dimers but not that of p65 dimers (compare Fig. 2A, lanes 3 and 4). The inhibition of p50 dimer DNA binding by GST-TAN-1C was concentration dependent (Fig. 2B). This subunit specificity resembles that of the protooncogene, Bcl-3, and is different from those of IκB-α and -β, which selectively interact with p65 (29, 30, 33). Interestingly, the ankyrin repeats of TAN-1 are more closely related to Bcl-3 (50% similarity and 29% identity) than IκB-α (45% similarity and 22% identity). These results suggest that NF-κB dimers containing the p50 subunit are a target for negative regulation by human Notch/TAN-1 molecules.

![Figure 1](image-url). Specificity of inhibition of DNA binding of nuclear NF-κB by recombinant TAN-1C. (A) PMA-induced nuclear extracts were assayed with bacterially expressed GST-TAN-1C or control protein, GST, in an EMSA using radiolabeled κB DNA. Lane 1, [32P]-κB DNA probe alone; lane 2, nuclear extracts (NE) with probe; lane 3, specific competitor (SC) (κB DNA); lane 4, nonspecific competitor (NSC) (Sp1 DNA); lane 5, TAN-1C (4 pmol); and lane 6, GST (4 pmol). The faster migrating band is considered a nonspecific binding component that may cross-react with κB DNA present in the nuclear extracts, as this complex does not supershift in the presence of anti-p50 or anti-p65 antibodies (data not shown). (B) The same nuclear extracts were analyzed in an EMSA using radiolabeled κB DNA. Lanes 1-4, TAN-1C (0, 1, 2, and 4 pmol); lane 5, GST (4 pmol); and lanes 6 and 7, p50 and p65 antibodies, respectively. (Bracket) Positions of immune complexes. (C) The same nuclear extracts were analyzed in an EMSA using radiolabeled κB and OTF1 probes. Lane 1, nuclear extract plus GST (4 pmol) and OTF1 probe; lane 2, nuclear extract plus TAN-1C (4 pmol) and OTF1 probe; lane 3, nuclear extract plus GST (4 pmol) and κB probe; and lane 4, nuclear extract plus TAN-1C (4 pmol) and κB probe. The positions of NF-κB and OTF1 are indicated.
Direct Binding of TAN-1 to NF-κB p50 Subunit. We did not observe GST-TAN-1C directly binding to the κB site on DNA (data not shown). Therefore, it may prevent DNA binding of p50-containing NF-κB complexes by binding to the p50 subunit. To demonstrate such a direct protein–protein interaction, GST-TAN-1C was tested for precipitation of in vitro-translated p50 and p65 on glutathione Sepharose beads. In vitro-translated 35S-labeled p50 and p65 products are shown in Fig. 3 A, lanes 1 and 2. GST-TAN-1C precipitated p50 but not p65 (Fig. 3 B, lanes 3 and 4). The GST control precipitated neither p50 nor p65 (Fig. 3 B, lanes 1 and 2), indicating that the inhibition of the DNA-binding activity of p50 is specific and dependent on a direct association between p50 and TAN-1. These results suggest that TAN-1 functions as a bona fide IκB protein.

TAN-1C Can Modulate NF-κB-Dependent Transactivation. We further investigated the effect of overexpressing the cytoplasmic domain of TAN-1 on κB-dependent transactivation in intact cells. In NTERA-2 cells, the high level expression of a chloramphenicol acetyltransferase (CAT) gene driven by the κB sites of the HIV-κB-LTR or of a luciferase gene driven by six reiterated κB sites is dependent on cotransfection of NTERA-2 cells with expression vectors for NF-κB proteins (31, 33, 40). As shown in Fig. 4 A, coexpression of TAN-1C or Bcl-3 decreased the κB-dependent transactivation of the luciferase reporter gene in a dose-dependent manner (Fig. 4 A). In this experiment, the ratio of p50 to p65 plasmids was 1:1. Similar results were obtained with a HIV-κB-LTR–driven CAT gene (data not shown). In the presence of increased concentrations of p50 expression vector (p50/p65 plasmid ratio = 6:1), a bimodal effect of TAN-1C was observed (Fig. 4 B). Whereas high concentrations of TAN-1C vector resulted in an inhibition of transactivation as seen in Fig. 4 A, lower concentrations of transfected TAN-1C vector resulted in an increased transactivation (Fig. 4 B). This behavior resembles that of Bcl-3 (compare Fig. 4 B, right). TAN-1, like Bcl-3, appeared to be able to reverse the transcriptional inhibition imposed by high amounts of p50 dimers. Higher levels of TAN-1 expression may also interfere with p50/p65 heterodimers resulting in a net inhibition of reporter gene expression. These data indicate that TAN-1C has the potential to facilitate NF-κB–dependent gene expression which has been shown to be an important step in T cell activation (43).

Sup-T1 T Cells Contain a NF-κB–TAN-1 Complex. The preceding experiments suggested a direct and functional interaction of TAN-1C with NF-κB in vitro and in vivo. We therefore sought evidence for a physical association between TAN-1 and p50 containing NF-κB complexes under physiologic conditions. We analyzed anti-p50 and anti-p65 immunoprecipitates from Sup-T1, a T cell line that contains copies of both the normal and truncated TAN-1 gene and U266, a mature B cell line (plasma cell) that does not express detectable levels of Notch protein. Preimmune IgG did not detect TAN-1 in either cell line (Fig. 5, lanes 1 and 2) and anti-TAN-1 antibody found no evidence of TAN-1-related peptides in the U266 control (Fig. 5, lane 3). However, anti-TAN-1 antibody did reveal the presence of two peptides in anti-NF-κB immunoprecipitates from Sup-T1 cell line cells. The 90-kD species observed is consistent with the truncated protein predicted from the sequence resulting from the chromosomal rearrangement seen in this cell line and certain T cell leukemias (8). The less abundant 100-kD species likely corresponds to a proteolytic product of human Notch, in that a peptide of identical molecular weight has been consistently observed.
Figure 4. TAN-1 modulates transactivation mediated by NF-κB. (A) Transactivation of 6 kb-luciferase reporter (0.3 μg) plasmids by transfection of NTera-2 cells with expression vectors encoding columns: 1, reporter plasmids; 2, vectors as used in 1 plus p65 (0.5 μg) and p50 (0.5 μg); 3–7, vectors as used in 2 plus increasing amounts of TAN-1 or Bcl-3 vector 0.1, 0.3, 0.5, 1, and 2 μg. (B) Column 1, reporter plasmid (0.3 μg); 2, vectors as 1 plus p65 (0.05 μg) and p50 (3 μg); 3–7, vectors as 2 plus increasing amounts of TAN-1 or Bcl-3 vector 0.1, 0.3, 0.5, 1, and 3 μg.

Discussion

In this paper we show that the intracellular domain of Notch/TAN-1 specifically inhibits NF-κB activity and binds p50 in vitro. Its transfection modulates κB-mediated transactivation. TAN-1 related peptides, including that predicted from the translocation event, are found associated with NF-κB in a leukemic T cell line.

These data suggest that membrane-associated Notch (TAN-1) may prevent nuclear localization of NF-κB in human T cells as has been proposed for Drosophila nuclear transcription factors (44).

Figure 5. TAN-1 interacts with NF-κB. U266 or Sup-T1 T cells were lysed and immunoprecipitated with anti-p50 or anti-p65 antibodies. The immunoprecipitates were analyzed by SDS-PAGE (4–20%) and transferred to PVDF membranes. Lanes 1 and 2, U266 or Sup-T1 T immunoprecipitates were probed with preimmune rabbit IgG that did not detect TAN-1 bands. Lanes 3–5, U266 or Sup-T1 T immunoprecipitates were probed with TAN-1 antibody that detected TAN-1 bands from Sup-T T cells but not from control cells, U266. Bands corresponding to IgG heavy and light chains from p50 and p65 antibodies that reacted with detection system, alkaline phosphatase–labeled anti–rabbit IgG (H+L) are also indicated.

2029 Guan et al.
as transcriptional activators through the κBF2-binding sites of the mouse Hairy enhancer of split 1 promoter (48). Interestingly, the Deltex–Notch interaction prevents the observed cytoplasmic retention of the suppressor of Hairless protein by Notch ankyrin repeats resulting in nuclear translocation (44). These observations highlight the significance of our findings in the context of a mechanism relevant to the human system in which Notch is thought to play a potentially pathogenic role.

Adjacent ankyrin repeats have been shown to mediate protein–protein interactions (30, 32, 49, 50). Mutations disrupting single ankyrin repeats in Bcl-3, pp40, and p105 rendered these proteins incapable of suppressing the DNA-binding activity of NF-κB or associating with NF-κB/Rel proteins. This demonstrates that ankyrin motifs are absolutely required for the functional interaction between IκB and NF-κB (30, 32). So far the ankyrin repeats of human Notch have not been demonstrated to associate with intracellular proteins. Our data suggest that members of the well-characterized NF-κB/Rel transcription factor family serve, under physiologic conditions, as signal transducers for Notch1/TAN-1 receptors. The structural and pathophysiologic analogy between the TAN-1 and Bcl-3 protooncogene is now further extended by a functional relationship: both proteins specifically bind the p50 NF-κB subunit and show similar effects on κB-dependent transactivation. The Bcl-3 protooncogene that shows increased expression in chronic lymphocytic leukemia cells containing the translocation t(14;19) (q32;q13.1), differs from TAN-1 in that it lacks a transmembrane domain, and is predominantly nuclear. However, earlier studies indicate that truncated, putatively activated forms of Notch without transmembrane and extracellular domains are translocated to the nucleus in transgenic flies and in transfected mammalian or Drosophila cells (13, 14, 47, 51). Sequence comparison and deletion analysis have identified two nuclear localization sequences that reside on either side of the Notch ankyrin repeats. Preliminary data indicate that truncated human Notch/TAN-1 is present in both the cytoplasm and nucleus (Guan, E., unpublished observations). These findings raise the possibility that the oncogenic and possibly physiologically activated forms of TAN-1 are truncated and, like Bcl-3, may act in the nucleus. Another Notch-related protein that may fall into a novel class of proteins with ankyrin repeats and a functional association with control of normal and neoplastic cell proliferation is the mouse mammary tumor gene product, int-3 (52). However, the mechanism(s) by which TAN-1 could contribute to malignancy has remained elusive. The family of Rel-related and ankyrin motif-containing proteins has been associated with tumorigenesis. v-Rel-containing viruses are highly transforming; c-Rel, p50B, Bcl-3, and TAN-1 are located at sites of recurrent translocations and genomic rearrangements (8, 40, 41, 53, 54). We are currently investigating whether TAN-1 can interact with several other Rel/NF-κB proteins and whether these alterations in p50 complexes can be consistently detected in these tumors. Inappropriately expressed human TAN-1 may contribute to tumorigenesis by regulating NF-κB gene expression (as seen for the c-Rel, p50B, and Bcl-3 genes) particularly when Notch has been affected by chromosomal translocation.

The function of Notch/TAN-1 as a regulator of NF-κB provides a preliminary understanding of its importance in human development, immunology, and oncogenesis.

We thank A. Grant, E. Max, L. Miele, L. Shelly, U. Sienbenlist, and K. Stein for helpful comments on the manuscript. We also thank E. Bonvini for preliminary purification of GST-TAN-1 fusion protein. We are most thankful to E. Lizzio, D. Farhcon, H. Mitchell, and T. Orevacz for excellent technical assistance. The Sup-T1 cell line was obtained through Dr. James Hoxie of the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Address correspondence to Dr. Ennan Guan, Laboratory of Cell Biology, Division of Monoclonal Antibodies, Center for Biology Evaluation and Research, Federal Drug Administration, Building 29B, Room 4G03, HFM558, 8800 Rockville Pike, Bethesda, MD 20892.

Received for publication 19 December 1995 and revised form 22 February 1996.

References
1. Kidd, S., M.K. Baylies, G.P. Gasic, and M.W. Young. 1989. Structure and distribution of the Notch protein in developing Drosophila [published erratum appears in Genes & Dev. 1989 Dec;3(12A):2020]. Genes & Dev. 3:1113–1129.
2. Heitler, P., and P. Simpson. 1993. Altered epidermal growth factor-like sequences provide evidence for a role of Notch as a receptor in cell fate decisions. Development (Camb.). 117:1113–1123.
3. Yochem, J., and I. Greenwald. 1989. glp-1 and lin-12, genes implicated in distinct cell–cell interactions in C. elegans, encode similar transmembrane proteins. Cell. 58:553–563.
4. Yochem, J., K. Weston, and I. Greenwald. 1988. The Caenorhabditis elegans lin-12 gene encodes a transmembrane protein with overall similarity to Drosophila Notch. Nature (Lond.). 335:547–550.
5. Greenwald, I., and G. Seydoux. 1990. Analysis of gain-of-function mutations of the lin-12 gene of Caenorhabditis elegans. Nature (Lond.). 346:197–199.
23. Kieran, M., V. Blank, F. Logeat, J. Vandenkerckhove, F. Lottspeich, O. Le Bail, M.B. Urban, P. Kourilsky, P.A. Baeuerle, and A. Israel. 1990. The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell. 62:1007–1018.

24. Ghosh, S., and D. Baltimore. 1990. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature (Lond.). 344:678–682.

25. Nolan, G.P., S. Ghosh, H.C. Liou, P. Tempst, and D. Baltimore. 1991. DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell. 64:961–969.

26. Duckett, C.S., N.D. Perkins, T.F. Kowalik, R.M. Schmid, E.S. Huang, A.S. Baldwin, Jr., and G.J. Nabel. 1993. Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). Mol. Cell. Biol. 13:1315–1322.

27. Beg, A.A., and A.S. Baldwin, Jr. 1993. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes & Dev. 7:2064–2070.

28. Schmitz, M.L., and P.A. Baeuerle. 1991. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO (Eur. Mol. Biol. Organ.) J. 10:3805–3817.

29. Haskill, S., A.A. Beg, S.M. Tompkins, J.S. Morris, A.D. Yurochko, A. Sampson-Johannes, K. Mondal, P. Ralph, and A.S. Baldwin, Jr. 1991. Characterization of an immediately early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell 65:1281–1289.

30. Wulczyn, F.G., M. Naumann, and C. Scheidereit. 1992. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B. Nature (Lond.). 358:597–599.

31. Franoso, G., V. Bours, S. Park, M. Tomita-Yamaguchi, G. Kelly, and U. Siebenlist. 1992. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature (Lond.). 359:339–342.

32. Inoue, J., L.D. Kerr, D. Rashid, N. Davis, H.R. Bose, Jr., and I.M. Verma. 1992. Direct association of pp40/I kappa B with p65/NF-kappa B transcription factors: role of ankyrin repeats in the inhibition of DNA binding activity. Proc. Natl. Acad. Sci. USA. 89:4333–4337.

33. Franoso, G., P. Biswas, G. Poli, L.M. Carlson, K.D. Brown, M. Tomita-Yamaguchi, A.S. Fauci, and U.K. Siebenlist. 1994. A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kB subunit p65 in vitro and may impair human immunodeficiency virus type 1 replication in these cells. J. Exp. Med. 180:1445–1456.

34. Hatada, E.N., A. Nieters, F.G. Wulczyn, M. Naumann, R. Meyer, G. Nucifora, T.W. McKeithan, and C. Scheidereit. 1992. The ankyrin repeat domains of the NF-kappa B pre-cursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. Proc. Natl. Acad. Sci. USA. 89:2489–2493.

35. Davis, N., S. Ghosh, D.I. Simmons, P. Tempst, H.C. Liou, D. Baltimore, and H.R. Bose, Jr. 1991. Rel-associated pp40: an inhibitor of the rel family of transcription factors. Science (Wash. DC). 253:1268–1271.

36. Shirakawa, F., and S.B. Mizel. 1989. In vitro activation and nuclear translocation of NF-kappa B catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. Mol. Cell Biol. 9:2424–2430.

37. Kerr, L.D., C.S. Duckett, P. Wamsley, Q. Zhang, P. Chiao, G. Nabel, T.W. McKeithan, P.A. Baeuerle, and I.M. Verma. 1992. The proto-oncogene bcl-3 encodes an I kappa B protein. Genes & Dev. 6:2352–2363.
38. Henkel, T., T. Machleidt, I. Alkalay, M. Kronke, Y. Ben-Neriah, and P.A. Baeuerle. 1993. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature (Lond.). 365:182-185.

39. Naumann, M., F.G. Wulczyn, and C. Scheidereit. 1993. The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF- kappa B. EMBO (Eur. Mol. Biol. Organ.) J. 12: 213-222.

40. Bours, V., G. Franzoso, V. Azarenko, S. Park, T. Kanno, K. Brown, and U. Siebenlist. 1993. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 72:729-739.

41. Ohno, H., G. Takimoto, and T.W. McKeithan. 1990. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 60: 991-997.

42. Dignam, J.D., R.M. Lebovitz, and R.G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489.

43. Kang, S.M., A.C. Tran, M. Grilli, and M.J. Lenardo. 1992. NF-kappa B subunit regulation in nontransformed CD4+ T lymphocytes. Science (Wash. DC). 256:1452-1456.

44. Matsuno, K., R.J. Diederich, M.J. Go, C.M. Blaumueller, and S. Artavanis-Tsakonas. 1995. Deltex acts as a positive regulator of Notch signaling through interactions with the Notch ankyrin repeats. Development (Camb.). 121:2633-2644.

45. Tannahill, D., S. Bray, and W.A. Harris. 1995. A Drosophila E(spl) gene is neurogenic in Xenopus: a green fluorescent protein study. Dev. Biol. 168:694-697.

46. Jennings, B., A. Preiss, C. Delidakis, and S. Bray. 1994. The Notch signaling pathway is required for Enhancer of split bHLH protein expression during neurogenesis in the Drosophila embryo. Development (Camb.). 120:3537-3548.

47. Fortini, M.E., I. Rebay, L.A. Caron, and S. Artavanis-Tsakonas. 1993. An activated Notch receptor blocks cell-fate commitment in the developing Drosophila eye. Nature (Lond.). 365:555-557.

48. Jarriault, S., C. Brou, F. Logeat, E.H. Schroeter, R. Kopan, and A. Israel. 1995. Signalling downstream of activated mammalian Notch. Nature (Lond.). 377:355-358.

49. Lux, S.E., K.M. John, and V. Bennett. 1990. Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins. Nature (Lond.). 344:36-42.

50. Thompson, C.C., T.A. Brown, and S.L. McKnight. 1991. Convergence of Ets- and notch-related structural motifs in a heteromeric DNA binding complex [see comments]. Science (Wash. DC). 253:762-768.

51. Rebay, I., R.G. Fehon, and S. Artavanis-Tsakonas. 1993. Specific truncations of Drosophila Notch define dominant activated and dominant negative forms of the receptor. Cell. 74: 319-329.

52. Robbins, J., B.J. Blondel, D. Gallahan, and R. Callahan. 1992. Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. J. Virol. 66:2594-2599.

53. Moore, B.E., and H.R. Bose, Jr. 1988. Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts. Virology. 162:377-387.

54. Sylla, B.S., and H.M. Temin. 1986. Activation of oncogenicity of the c-rel proto-oncogene. Mol. Cell Biol. 6:4709-4716.